

# LITESEC-T3SS - Light-controlled protein delivery into eukaryotic cells with high spatial and temporal resolution

Florian Lindner, Bailey Milne-Davies, Katja Langenfeld, and Andreas Diepold\*

Max-Planck-Institute for Terrestrial Microbiology, Department of Ecophysiology, Karl-von-Frisch-Str. 10, 35043 Marburg, Germany

\* For correspondence: andreas.diepold@mpi-marburg.mpg.de, +49-6421-178302

## 1 **Abstract**

2 Many bacteria employ a type III secretion system (T3SS), also called injectisome, to translocate  
3 proteins into eukaryotic host cells through a hollow extracellular needle. The system can efficiently  
4 transport heterologous cargo, which makes it a uniquely suited tool for the translocation of  
5 proteins into eukaryotic cells. However, the injectisome indiscriminately injects proteins into any  
6 adjoining eukaryotic cell, and this lack of target specificity currently limits its application in  
7 biotechnology and healthcare. In this study, we exploit the dynamic nature of the T3SS to control  
8 protein secretion and translocation into eukaryotic cells by light. By combining optogenetic  
9 interaction switches with the dynamic cytosolic T3SS component SctQ, the cytosolic availability of  
10 SctQ and in consequence T3SS-dependent effector secretion can be regulated by external light.  
11 The resulting system, which we call LITESEC-T3SS (**L**ight-**i**nduced **t**ranslocation of **e**ffectors through  
12 **s**equestration of **e**ndogenous **c**omponents of the **T3SS**), allows rapid, specific, and reversible  
13 activation or deactivation of the T3SS upon illumination. We demonstrate the application of the  
14 system for light-regulated translocation of a heterologous reporter protein into cultured  
15 eukaryotic cells. LITESEC-T3SS represents a new method to achieve unparalleled spatial and  
16 temporal resolution for the controlled protein translocation into eukaryotic host cells.

## 17 **Introduction**

### 18 **The bacterial type III secretion injectisome**

19 The injectisome is a bacterial nanomachine capable of translocating proteins into eukaryotic host cells  
20 in a one-step export mechanism<sup>1,2</sup>. The core components of the injectisome, or type III secretion  
21 system (T3SS)<sup>5</sup> are shared with the bacterial flagellum<sup>3,4</sup>. The injectisome consists of (i) an extracellular  
22 needle formed by helical polymerization of a small protein and terminated by a pentameric tip  
23 structure, (ii) a series of membrane rings that span both bacterial membranes and embed (iii) the  
24 export apparatus, formed by five highly conserved hydrophobic proteins thought to gate the export  
25 process, and (iv) a set of essential cytosolic components, which cooperate in substrate selection and  
26 export (Fig. 1A).

27 The injectisome is an essential virulence factor for many pathogenic Gram-negative bacteria, including  
28 *Salmonella*, *Shigella*, pathogenic *Escherichia coli*, and *Yersinia*<sup>5</sup>. It is usually assembled upon entry into  
29 a host organism, but remains inactive until contact to a host cell has been established. At this point,  
30 the injectisome exports two translocator proteins that form a pore in the host membrane, and a pool  
31 of so-called T3SS effector proteins that are translocated into the host cell.

32 The Gram-negative enterobacterium *Y. enterocolitica* uses the T3SS to translocate six Yop (*Yersinia*  
33 outer protein) effector proteins into phagocytes, which prevent phagocytosis and block pro-  
34 inflammatory signaling<sup>7</sup>. In this study, we use the *Y. enterocolitica* strain IML421asd ( $\Delta$ HOPEMTasd)<sup>8</sup>,  
35 where these six virulence effectors have been deleted, and which is additionally auxotrophic for the  
36 cell wall component diaminopimelic acid. The strain is therefore non-pathogenic, but possesses a  
37 functional T3SS. Secretion of effector proteins can be triggered *in vivo* by host cell contact or *in vitro*  
38 by low Ca<sup>2+</sup> levels in the medium<sup>9</sup>.

39

### 40 **The T3SS as a protein translocation device**

41 Being a machinery that evolved to efficiently translocate proteins into eukaryotic cells, the T3SS has  
42 been successfully used to deliver protein cargo into a wide variety of eukaryotic target cells for  
43 different purposes such as vaccination, immunotherapy, and gene editing (reviewed in ref. <sup>10</sup>). Export  
44 through the T3SS is fast and efficient: More than 10<sup>6</sup> effectors can be translocated into a single host  
45 cell at rates of several hundred effectors per second for one injectisome<sup>11-14</sup>. Short N-terminal  
46 secretion signals mark cargo proteins for delivery by the T3SS<sup>15,16</sup>. The size and structure of the cargo  
47 proteins can influence translocation rates, and very large or stably folded proteins (such as GFP or

---

<sup>5</sup> In this manuscript, T3SS refers to the virulence-associated T3SS. The common „Sct“ nomenclature<sup>49</sup> is used for T3SS components, see ref. <sup>39</sup> for species-specific names.

48 dihydrofolate reductase) are exported at a lower rate. However, most cargoes, including large proteins  
49 with molecular weights above 60 kDa, can be exported by the T3SS<sup>14,17,18</sup>. Protein translocation into  
50 host cells can be titrated by adjusting the expression level and multiplicity of infection (ratio of bacteria  
51 and host cells). Within the host, the T3SS secretion signal can be removed by site-specific proteases or  
52 cleavage at the C-terminus of a ubiquitin domain by the native host cell machinery, and subcellular  
53 localization can be influenced using nanobodies co-translocated by the T3SS<sup>14,19</sup>. Taken together, these  
54 properties make the T3SS an efficient and versatile tool for protein delivery into eukaryotic cells<sup>10,14</sup>.

55 T3SS inject effector proteins into any eukaryotic host cell as soon as they are in contact. Lack of target  
56 specificity is therefore a main obstacle in the further development and application of T3SS-based  
57 protein delivery systems<sup>20,21</sup>.

58

### 59 Dynamics of the cytosolic components of the T3SS and its link to effector secretion

60 Four soluble cytosolic components of the T3SS (SctK, L, Q, N) form an interdependent complex at the  
61 proximal interface of the injectisome<sup>22-29</sup> (Fig. 1A). As these proteins interact with effectors and their  
62 chaperones with a graded affinity matching the export order of the effectors, they were termed  
63 “sorting platform”<sup>30</sup>. Our group recently discovered that the sorting platform proteins of the  
64 *Y. enterocolitica* T3SS constantly exchange between the injectisome and a cytosolic pool (Fig. 1A), and  
65 that this exchange is linked to protein secretion by the T3SS<sup>25,31</sup>. We rationalized that the constant  
66 shuttling of these essential T3SS components should allow to control T3SS activity through reversible  
67 sequestration of one of the cytosolic proteins, thereby establishing a completely new way of regulating  
68 the T3SS.

69

### 70 Optogenetic control of protein interactions

71 Optogenetics combines optical and genetic methods to precisely and reversibly control gain or loss of  
72 protein function in living cells or tissues. It allows fast (within milliseconds) and specific (to single  
73 proteins) control of defined events in biological systems<sup>32</sup>, giving optogenetic approaches an  
74 advantage over knockdown, overexpression, or mutant strain analysis, which often display slower  
75 activation and a broader effect<sup>33</sup>. Optogenetic protein interaction switches use light-induced  
76 conformational changes of specific proteins, often light-oxygen-voltage (LOV) domain proteins, to  
77 control protein-protein interactions by light<sup>34,35</sup>. They usually consist of homo- or hetero-dimers whose  
78 affinities are strongly altered upon irradiation by light of a certain wavelength. Mutations of specific  
79 amino acids in the optogenetic interaction domains can modulate binding affinities and the  
80 corresponding dissociation or return rates<sup>35,36</sup>.

81 Optogenetic interaction switches were established and have mainly been studied in eukaryotic cells<sup>37</sup>.  
82 In this work, we therefore tested the applicability of two different optogenetic interaction switches in  
83 bacteria: (i) The LOVTRAP system (LOV), which consists of the two interacting proteins LOV2 (a photo  
84 sensor domain from *Avena sativa* phototropin 1) and Zdk1 (Z subunit of the protein A), that bind to  
85 each other in the dark. Upon irradiation with blue light, LOV2 undergoes a conformational change and  
86 Zdk1 is released<sup>35</sup>. (ii) The iLID system, which employs the interaction of iLID, derived from a LOV2  
87 domain from *Avena sativa* phototropin 1, with a smaller binding partner, SspB\_Nano. The iLID system  
88 has a low binding affinity in the dark and a high affinity upon irradiation with blue light<sup>34,36</sup>. LOV and  
89 iLID systems therefore react to light in opposite directions, which allows to specifically release a bait  
90 protein (and, subsequently, to activate processes that require its presence) in the dark or upon  
91 illumination, respectively.

92 To establish the use of optogenetic interaction switches in bacteria, we first assessed the effect of  
93 illumination on the different switches by light microscopy, using fluorescently labeled bait proteins.  
94 Next, we applied the switches to control the availability of the essential cytosolic T3SS component  
95 SctQ and, in consequence, secretion of cargo proteins through the T3SS, by light. We optimized the  
96 systems by defining suitable versions of the switches and adjusting the expression ratio of anchor and  
97 bait proteins. As proof of concept, we show the light-dependent translocation of a heterologous cargo  
98 protein into eukaryotic host cells. The successful development of the LITESEC system presents a  
99 blueprint for the application of optogenetic interaction switches in prokaryotes, and opens widespread  
100 opportunities for using the T3SS as a specific and precisely controllable tool to deliver proteins of  
101 interest into eukaryotic cells.

102 **Results**

103 Controlling protein secretion and translocation by the T3SS with light

104 To establish a method to control protein translocation by the T3SS, we took advantage of our recent  
105 finding that some essential cytosolic T3SS components constantly exchange between the cytosol and  
106 the injectisome<sup>25,31</sup>. We combined one of these components, SctQ, with one partner domain of an  
107 optogenetic interaction switch, and targeted the other partner domain to the bacterial inner  
108 membrane (IM) by adding an N-terminal transmembrane helix. This allowed to control SctQ availability  
109 in the cytosol, and therefore T3SS-based protein export and translocation into host cells, by light. To  
110 be able to control T3SS activity in both directions, we developed two complementary systems:

111 **A) LITESEC-supp, a system that confers suppression of T3SS-dependent protein translocation by blue**  
112 **light illumination**

113 **B) LITESEC-act, a system that confers activation of T3SS-dependent protein translocation by blue**  
114 **light illumination**


115 Both systems rely on two interaction partners which we have engineered:

116 (i) A membrane-bound **anchor protein**, which is a fusion between the N-terminal transmembrane helix  
117 (TMH) of a well-characterized transmembrane protein, *Escherichia coli* TatA, extended by two amino  
118 acids (Val-Leu) for more stable insertion in the IM, a Flag peptide for detection and spacing, and the  
119 larger domain of the respective optogenetic interaction switches, **iLID** (for LITESEC-supp) or **LOV2** (for  
120 LITESEC-act). The resulting fusion proteins, **TMH-iLID / TMH-LOV2**, are expressed from a plasmid.

121 (ii) A **bait protein**, which consists of a fusion between the essential cytosolic T3SS component SctQ and  
122 the smaller domain of the interaction switches, **SspB\_Nano** (LITESEC-supp) / **Zdk1** (LITESEC-act). The  
123 resulting fusion proteins, **SspB\_Nano-SctQ / Zdk1-SctQ**, replace the wild-type SctQ protein on the  
124 *Y. enterocolitica* virulence plasmid by allelic exchange of the genes<sup>38</sup>.

125 Co-expression of both proteins provides the basis for light-controlled protein translocation by the T3SS  
126 (Fig. 1). For the iLID-based **LITESEC-supp system**, the bait protein is tethered to the membrane anchor  
127 in the light, and SctQ is therefore not available to interact with the T3SS (Fig. 1B). As SctQ is essential  
128 for the function of the T3SS, protein secretion by the T3SS is prevented (Fig. 1C). In the dark, the bait  
129 protein is not bound to the membrane, and can therefore functionally interact with the T3SS, allowing  
130 protein secretion by the T3SS (Fig. 1A). Conversely, in the LOV-based **LITESEC-act system**, the bait  
131 protein is released from the membrane upon irradiation with blue light, licensing protein secretion by  
132 the T3SS (Fig. 1).

133




134

135 **Fig. 1: Working principle of the LITESEC systems – light-controlled activation and deactivation of protein**  
 136 **translocation by the type III secretion system**

137 **(A)** Schematic representation of the active T3SS injectisome (modified from ref. 39). Left side, main  
 138 substructures; right side, dynamic cytosolic T3SS components. Effector translocation by the T3SS is licensed by  
 139 the functional interaction of the unbound bait-SctQ fusion with the T3SS. **(B)** Different states of the bait and  
 140 anchor proteins in dark and light conditions. In the LITESEC-supp system (top), the bait protein, a fusion of the  
 141 smaller interaction switch domain SspB\_Nano and the essential T3SS component SctQ, is tethered to the inner  
 142 membrane (IM) by a membrane anchor, a fusion of a transmembrane helix (TMH) and the larger interaction  
 143 switch domain, iLID, in the light, and gets released in the dark. Conversely, in the LITESEC-act system (bottom),  
 144 the bait protein, a fusion of the smaller interaction switch domain, Zdk1, and the essential T3SS component  
 145 SctQ, is tethered to the membrane anchor, a TMH fusion of the larger interaction switch domain, LOV2, in the  
 146 dark, and gets released by illumination. **(C)** Sequestration of the bait-SctQ fusion protein to the membrane  
 147 prevents effector secretion. HM, host membrane; OM, bacterial outer membrane; IM, bacterial inner  
 148 membrane.

149 Characterization of optogenetic sequestration systems in *Y. enterocolitica*

150 To assess the function and efficiency of the used optogenetic interaction switches as sequestration  
151 systems in prokaryotes, and to monitor their dynamics, we visualized the components of iLID- and  
152 LOV-based sequestration systems<sup>34,35</sup> in live *Y. enterocolitica* by time-lapse fluorescence microscopy.  
153 We coexpressed the anchor protein with a version of the corresponding bait protein where SctQ was  
154 replaced by mCherry to allow for a characterization of the switch by fluorescence microscopy. Initially,  
155 we confirmed that mCherry fused to the membrane anchor showed a strict membrane localization  
156 (Suppl. Fig. 1), indicating a stable fusion and a functional TMH motif. Next, the localization of mCherry-  
157 bait fusions was determined by fluorescence microscopy in live *Y. enterocolitica* expressing the  
158 corresponding unlabeled anchor proteins (Suppl. Table 1). Bacteria were grown in the dark and the  
159 distribution of the bait proteins was monitored before and after a short pulse of blue light (Fig. 2AB).  
160 To quantify the change of the normalized fluorescence signal across the bacterial cells, line scans were  
161 performed (Fig. 2CD). For the iLID system, the fluorescence signal of the bait-mCherry was cytosolic in  
162 the pre-activated state. After activation of the interaction switch with blue light, the fluorescence  
163 signal partly shifted to the membrane (Fig. 2A) and returned to the cytosol within the next minutes  
164 (Fig. 2C). In contrast, for the LOV-based sequestration system, the fluorescence signal of the bait-  
165 mCherry was mainly membrane localized in the pre-activated state. Activation with blue light led to  
166 only a minor relocalization of the signal from the membranes to the cytosol (Fig. 2BD), suggesting that  
167 the majority of bait protein remained bound to the anchor even after illumination.  
168



170 **Fig. 2: Activation and recovery kinetics of optogenetic sequestration systems**

171 (A/B) Fluorescence micrographs of mCherry-labeled bait proteins in the iLID-based (A) and LOV-based (B)  
172 sequestration systems, before (left) and directly after (right) illumination with blue light. (C/D) Representative  
173 fluorescence signal quantification across bacteria over time in the iLID-based (C) and LOV-based (D)  
174 sequestration systems; dark grey: membrane, light grey: cytosol. Insets: Fluorescence relocalization factor (fluor.  
175 reloc. =  $R_{\text{post-light}}/R_{\text{pre-light}}$ , where R represents the ratio of fluorescence intensities at the membrane and in the  
176 cytosol, before and after illumination, respectively), based on 121-131 line scans across five cells per strain and  
177 time point. Error bars represent the standard deviation, \*,  $p < 0.05$ ; \*\*\*,  $p < 0.001$  against no relocalization in a  
178 two-tailed homoscedastic t-test.

179


180 Development and characterization of LITESEC strains

181 For the development of the LITESEC strains, we replaced SctQ with the bait fusion proteins Zdk1-SctQ  
182 or SspB\_Nano-SctQ at its native genetic location via allelic exchange. We confirmed the stability of the  
183 fusion proteins in the LITESEC strains by Western blot (Suppl. Fig. 2). Protein secretion in wild-type  
184 *Y. enterocolitica* was not influenced by the used illumination (Suppl. Fig. 3A), and the blue light had no  
185 influence on growth of *Y. enterocolitica* (Suppl. Fig. 3B).

186 Inhibition of protein secretion by illumination in the LITESEC-supp system

187 Can we use LITESEC to control T3SS secretion by light? We first tested the LITESEC-supp1 system,  
188 designed to suppress T3SS protein secretion upon illumination (Table 1), in an *in vitro* protein secretion  
189 assay under conditions that usually lead to effector secretion (presence of 5 mM EGTA in the  
190 medium)<sup>9</sup>. The control strain lacking the membrane anchor secreted effectors irrespective of the  
191 illumination (Fig. 3A, lanes 4, 5), confirming the functionality of the used SctQ fusion protein. Strikingly,  
192 the LITESEC-supp1 system showed a high level of secretion when grown in the dark, but strongly  
193 reduced secretion when grown under blue light (Fig. 3A, lanes 6, 7). To quantify the difference of  
194 secretion under light and dark conditions, we define the light/dark secretion ratio (L/D ratio) as the  
195 ratio of secretion efficiency under light and dark conditions. For the LITESEC-supp1 system, the L/D  
196 ratio was 0.28, with normalized secretion efficiencies of  $23.5 \pm 8.1\%$  and  $85.1 \pm 5.1\%$  in light and dark  
197 conditions, respectively.





198

199 **Fig. 3: Secretion of effector proteins by the type III secretion system can be controlled by light**


200 *In vitro* secretion assay showing light-dependent export of native T3SS substrates (indicated on the right) in the  
201 LITESEC-supp1 strain. Proteins secreted by  $3 \times 10^9$  bacteria during a 180 min incubation period were precipitated  
202 and analyzed by SDS-PAGE. A strain lacking the membrane anchor (MA), the wild-type strain  $\Delta$ HOPENTasd and  
203 the T3SS-negative strain  $\Delta$ SctD were used as controls. MW, molecular weight in kDa.

204

205 Improved functionality of the LITESEC-act system with a mutated anchor (V416L)

206 We next tested the LITESEC-act1 system, designed for induction of secretion by blue light illumination  
207 (Table 1), and detected only a very weak activation of protein export under light conditions (Fig. 4,  
208 lanes 1-2). Based on the fact that secretion was wild-type-like in the absence of the membrane anchor  
209 (Fig. 4, lane 7), and the results of the earlier sequestration experiment (Fig. 2BD), we concluded that  
210 bait and anchor interact too strongly in the LITESEC-act1 system. Therefore, we constructed and tested  
211 additional versions of the system, using the mutated anchor version V416L, which displays a weaker  
212 affinity to the bait<sup>35</sup>. We hypothesized that a lower anchor/bait expression ratio could additionally lead  
213 to more efficient release of the bait and activation of T3SS secretion upon illumination, and expressed  
214 the V416L version of the anchor both from the medium-high copy pBAD expression vector used  
215 previously (LITESEC-act2), and a constitutive low-copy vector, pACYC184 (LITESEC-act3). The response  
216 of the resulting LITESEC systems (Table 1) to light was tested in an *in vitro* secretion assay. LITESEC-  
217 act2 showed significant induction of protein secretion in the light, compared to dark conditions (L/D  
218 ratio 2.16, Fig. 4, lanes 3-4). Even more markedly, LITESEC-act3 allowed an almost complete activation  
219 of secretion upon illumination (L/D ratio 4.18, Fig. 4, lanes 5-6). Both new strains retained the low level

220 of export in the dark. We also expressed the anchor for the LITESEC-supp system from pACYC184. The  
 221 resulting LITESEC-supp2 system showed efficient secretion in the dark and strong suppression of  
 222 secretion upon illumination (L/D ratio 0.26), comparable with the LITESEC-supp1 system (Fig. 4, lanes  
 223 8-11).



224

225 **Fig. 4: Secretion efficiency and light responsiveness in different versions of the LITESEC strains**

226 (A) *In vitro* secretion assay showing light-dependent export of native T3SS substrates (indicated on the right) in  
 227 various variants of the LITESEC-act strains (lanes 1-7) and LITESEC-supp strains (lanes 8-12), as indicated below.  
 228 Proteins secreted by  $3 \times 10^9$  bacteria during a 180 min incubation period were precipitated and analyzed by SDS-  
 229 PAGE. MA, expression level of membrane anchor; +, high expression level; (+), low expression level; -, no  
 230 expression. \*, V416L anchor mutant. (B) Quantification of secretion efficiency and light/dark secretion ratio (L/D  
 231 ratio) for the different LITESEC strains and illuminations indicated above (as in (A)). Secretion efficiency was  
 232 determined by gel densitometry for the YopB/LcrV/YopD/YopN bands and normalized for the secretion  
 233 efficiency in wild-type strains (lane 13 in (A)),  $n=3-7$ , error bars display standard deviation. \*\*,  $p<0.01$ ; \*\*\*,  
 234  $p<0.001$  in a two-tailed homoscedastic t-test; n.s., difference not statistically significant.

235

Optogenetic T3SS control system	Anchor ( <i>plasmid</i> )	Bait ( <i>endogenous expression</i> )	Properties
LITESEC-supp1 LITESEC-supp2	TMH-FLAG-iLID ( <i>pBAD</i> ) TMH-FLAG-iLID ( <i>pACYC184</i> )	SspB_Nano-SctQ	Suppression of T3SS-based protein secretion upon illumination by membrane sequestration of essential cytosolic T3SS component
LITESEC-act1 LITESEC-act2 LITESEC-act3	TMH-FLAG-LOV2 ( <i>pBAD</i> ) TMH-FLAG-LOV2 <sub>V416L</sub> ( <i>pBAD</i> ) TMH-FLAG-LOV2 <sub>V416L</sub> ( <i>pACYC184</i> )	Zdk1-SctQ	Activation of T3SS-based protein secretion upon illumination by release of essential cytosolic T3SS component

236

237 **Table 1: Schematic overview of the LITESEC systems and their optogenetic components**


238 Overview of the interaction partners and their properties. All bait proteins are expressed from their native  
239 genetic locus. TMH, extended transmembrane helix (see material and methods for details).

240

241 Light-dependent activation of the T3SS depends on the anchor/bait ratio

242 To assess whether the changed secretion efficiencies are indeed due to the lower expression of the  
243 anchor proteins in the new strains, we determined the expression levels by immunoblot. As expected,  
244 the anchor proteins expressed from the pBAD plasmids in the LITESEC-act2/-supp1 strains show a  
245 higher expression level than the anchor proteins expressed from the pACYC184 plasmid in the LITESEC-  
246 act3/-supp2 strains (Suppl. Fig. 4). To more thoroughly explore the connection between the  
247 anchor/bait expression ratio and the responsiveness of the T3SS to illumination, we compared the  
248 secretion levels under light and dark conditions for different expression levels of the anchor in the  
249 LITESEC-act2 system. The results show that indeed, the light responsiveness of the system (the  
250 difference between secretion levels under light and dark conditions) was optimal for intermediate  
251 anchor expression levels (Fig. 5A-C), corresponding to anchor/bait ratios of about one to two (Fig. 5D  
252 and Suppl. Methods)

253




254

255 **Fig. 5: The expression ratio of anchor and bait protein dictates the function and light responsiveness of protein**  
 256 **secretion in LITESEC-act2.**

257 **(A)** *In vitro* secretion assay showing light-dependent export of native T3SS substrates in the LITESEC-act2 strain  
 258 at different induction levels of anchor expression. **(B)** Quantification of secretion efficiency and light/dark  
 259 secretion ratio (L/D ratio) for the different expression levels indicated above (as in (A)). **\*/\*\*/\*\***,  
 260  $p < 0.05/0.01/0.001$  in a two-tailed homoscedastic t-test. **(C)** Western blot anti-FLAG of total cellular protein of  
 261  $2 \times 10^9$  bacteria in the indicated strains. Below, resulting anchor/bait ratio (see Suppl. Methods for details). **(D)**  
 262 Correlation between light/dark secretion ratio (L/D ratio) and anchor/bait ratio. Labels indicate anchor induction  
 263 levels (arabinose concentrations for LITESEC-act2); the grey dashed line denotes an L/D ratio of 1, indicating  
 264 non-light-regulated secretion;  $n = 3-4$  for all experiments.

265 The export of heterologous substrates by the T3SS can be controlled by light

266 The T3SS-dependent export of heterologous cargo has been shown and applied for many purposes in  
267 earlier studies<sup>10,14,20</sup>. To confirm that we can control the export of heterologous proteins in the LITESEC  
268 strains, we combined the LITESEC-act3 and -supp2 systems with a plasmid expressing a heterologous  
269 cargo protein, the luciferase NanoLuc, fused to a short N-terminal secretion signal, YopE<sub>1-53</sub><sup>16,40,41</sup>, and  
270 a C-terminal FLAG tag for detection. The cargo protein was exclusively exported in light conditions by  
271 the LITESEC-act3 strain, and exclusively in the dark by the LITESEC-supp2 strain, whereas export was  
272 light-independent in a wild-type strain (Fig. 6).



273

274 **Fig. 6: Heterologous cargo can be exported in a light-dependent manner.**


275 (A) *In vitro* secretion assay showing light-dependent export of YopE<sub>1-53</sub>-NanoLuc-FLAG (see scheme on top; exp.  
276 size, 28.7 kDa), in the indicated strains. Western blot using anti-FLAG antibodies. Left side, molecular weight in  
277 kDa. (B) Quantification of light-dependent YopE<sub>1-53</sub>-NanoLuc-FLAG export by densitometric analysis of Western  
278 blots, normalized by average secretion of the wild-type control (WT), n=3, error bars display the standard error  
279 of the mean. L/D ratio, ratio of secretion under light and dark conditions.

280

281 Kinetics of light-induced T3SS activation and inactivation

282 How efficiently can the LITESEC system be inactivated, and what are the kinetics of light-induced T3SS  
283 activation and deactivation? Protein secretion for the LITESEC-act3 and -supp2 strains was analyzed  
284 for bacteria incubated consecutively for 60 min under inactivating conditions (dark for LITESEC-act3,  
285 light for LITESEC-supp2), 60 min under activating conditions, and another 60 min under inactivating

286 conditions. After each incubation period, the culture medium was replaced, and a sample was tested  
287 for secretion by SDS-PAGE and Western Blot. Secretion of the heterologous export substrate YopE<sub>1-53</sub>-  
288 NanoLuc-FLAG in LITESEC-act3 was specifically induced in light conditions, and efficiently suppressed  
289 in the dark, whereas LITESEC-supp2 displayed the opposite behavior (Fig. 7). The WT strain  
290 continuously secreted proteins irrespective of the illumination. These results show that the activity of  
291 the LITESEC systems can be efficiently toggled. To more precisely determine the activation and  
292 deactivation kinetics, we used a sensitive bioluminescence-based luciferase assay<sup>42</sup> to quantify the  
293 export of the reporter protein YopE<sub>1-53</sub>-NanoLuc-FLAG in the different LITESEC strains under changing  
294 illumination. In the LITESEC-supp2 strain, secretion of the heterologous substrate dropped to  
295 background levels within four to eight minutes after the start of blue light illumination, and recovered  
296 within the first four minutes after shifting the bacteria to dark conditions again. The LITESEC-act3 strain  
297 showed an increase of secretion activity over 20 minutes in light conditions, and required 12-16  
298 minutes to shut down secretion in the dark (Suppl. Fig. 5).



299

300 **Fig. 7: Secretion of effector proteins can be controlled by light over time.**


301 (A/B) Export of the heterologous substrate YopE<sub>1-53</sub>-NanoLuc-FLAG (A) and native T3SS substrates (B) in the  
302 indicated strains. Secretion-competent bacteria were subsequently incubated under inactivating, activating and  
303 inactivating light conditions for 60 min each, as indicated. (C) Quantification of the relative export efficiency  
304 (normalized to the wild-type level in the third incubation period) of the strains and conditions shown in (A) and  
305 (B) for export of YopE<sub>1-53</sub>-NanoLuc-FLAG (filled circles, continuous line) and endogenous T3SS translocator  
306 proteins (empty circles, dashes line); n=3, error bars denote standard deviation.

307

308 Light-induced protein translocation into eukaryotic host cells

309 Having found that secretion of heterologous T3SS substrates can be tightly controlled by the LITESEC  
310 system, we wanted to employ the LITESEC-act system to control the injection of a cargo protein,  
311 YopE<sub>1-53</sub>- $\beta$ -lactamase, into eukaryotic host cells upon illumination. Translocation of  $\beta$ -lactamase can  
312 be visualized by the cleavage of a Förster resonance energy transfer (FRET) reporter substrate, CCF2,  
313 within host cells<sup>43,44</sup>, which results in a green to blue shift in the emission wavelength. As expected, a  
314 wild-type strain translocated the YopE<sub>1-53</sub>- $\beta$ -lactamase reporter substrate into a high fraction of host  
315 cells irrespective of the illumination. The negative control, the same strain expressing the  $\beta$ -lactamase  
316 reporter without a secretion signal, displayed a significantly lower rate of blue fluorescence (Fig. 8A),  
317 showing that translocation was T3SS-dependent. The LITESEC-act3 strain translocated the transporter  
318 in a light-dependent manner, leading to a significantly higher fraction of translocation-positive host  
319 cells in light than in dark conditions (close to the positive and negative controls, respectively; Fig. 8).  
320 In contrast, the LITESEC-supp2 strain showed the opposite behavior (Fig. 8). Taken together, these  
321 results confirm that translocation of heterologous proteins into eukaryotic host cells by the T3SS can  
322 be controlled by external light.

323



324

325 **Fig. 8: Light-dependent translocation of heterologous cargo into eukaryotic host cells**

326 (A) Fluorescence micrographs depicting cultured HEp-2 cells that have been incubated with the indicated  
 327 LITESEC strains expressing either a heterologous T3SS substrate, YopE<sub>1-53</sub>-β-lactamase, or β-lactamase without  
 328 a secretion signal as a negative control. Translocation of β-lactamase is detected by cleavage of the intracellular  
 329 β-lactamase substrate CCF2 (leading to loss of FRET, and a transition from green to blue fluorescence emission).  
 330 Scale bar, 50 μm. (B) Fraction of β-lactamase-positive HEp-2 cells (blue fluorescence). (C) Quantification of the  
 331 fluorescence ratio of CCF2 donor fluorescence (indicative of β-lactamase translocation) and FRET fluorescence  
 332 for (A). For panels B-C, 2226-2694 cells from 25-28 fields of view from 3 independent experiments were analyzed  
 333 per strain and condition for the LITESEC strains (671-995 cells from 8-10 fields of view from 3 independent  
 334 experiments for the controls). Error bars display the standard error of the mean amongst fields of view. \*\*\*,  
 335 p<0.001 in a two-tailed homoscedastic t-test; n.s., difference not statistically significant.



336 **Discussion**

337 *(See Supplementary Information for a more detailed discussion of activation dynamics and applications*  
338 *of the LITESEC system.)*

339 **Controlling protein secretion and translocation by the T3SS with light**

340 To overcome the lack of specificity of T3SS-dependent protein secretion and translocation into  
341 eukaryotic cells, we aimed to control T3SS activity by external light. Our solution exploits the recently  
342 uncovered dynamic exchange of various essential T3SS components between an injectisome-bound  
343 state and a freely diffusing cytosolic state<sup>25,31</sup> to control T3SS-dependent protein secretion by protein  
344 sequestration. SctQ, an essential and dynamic cytosolic component of the T3SS<sup>31</sup>, was genetically  
345 fused to one interaction domain of two optogenetic sequestration systems, the iLID and LOVTRAP  
346 systems<sup>35,36,45</sup>, while the membrane-bound interaction domain was co-expressed *in trans*. The two  
347 versions of the resulting LITESEC-T3SS system (**L**ight-**i**nduced **s**ecretion of **e**ffectors through  
348 **s**equstration of **e**ndogenous **c**omponents of the **T3SS**) can be applied in opposite directions: in the  
349 LITESEC-supp system, protein export is suppressed by blue light illumination; the LITESEC-act system  
350 allows to activate secretion by blue light.

351 The LITESEC-supp1 system, which is based on the iLID optogenetic interaction switch<sup>34</sup> (**T**able 1),  
352 showed a significant reaction to light (light/dark secretion ratio of 0.28; 24% vs. 85% of wild-type  
353 secretion under light and dark conditions, respectively; **F**ig. 3). Expression of the membrane anchor  
354 from a constitutively active promoter on a low copy plasmid, pACYC184 (LITESEC-supp2) retained the  
355 light/dark secretion ratio (L/D ratio of 0.26; 24% vs. 93% WT secretion; **F**ig. 4), with the additional  
356 advantage that expression of the membrane anchor is constitutive.

357 For many applications, activation of T3SS protein export upon illumination is preferable. The LITESEC-  
358 act1 system, which is based on the LOV optogenetic interaction switch<sup>35</sup>, only achieved weak activation  
359 of T3SS secretion upon illumination (**F**ig. 4). LITESEC-act2, which uses the V416L mutation in the anchor  
360 protein<sup>46</sup> to decrease the affinity between anchor and bait, could be activated by light more efficiently.  
361 Even more strikingly, LITESEC-act3, featuring a reduced expression level of the V416L variant of the  
362 membrane anchor, led to a strong activation of T3SS protein secretion upon illumination, while  
363 retaining the tight suppression of secretion in the dark (L/D ratio of 4.2; 66% vs. 16%; **F**ig. 4).

364 Notably, the export of heterologous cargo was entirely light-dependent (no visible export under  
365 inactive conditions; **F**ig. 6). In contrast, endogenous T3SS translocator proteins were still secreted to a  
366 basal level under inactivating light conditions, even in the most tightly controlled strains (LITESEC-  
367 act3/-supp2; **F**ig. 4). This might indicate that the export of heterologous cargo is regulated differently  
368 from the export of the endogenous translocators, which for example also involves protein-specific

369 chaperones. While this hypothesis remains to be rigorously tested, it highlights that beyond their  
370 application, LITESEC and similar optogenetic approaches can help to better understand the underlying  
371 biological systems.

372 To explore the influence of the anchor/bait expression ratio on light control of the T3SS in more detail,  
373 we measured the light-dependent activation of the LITESEC-act2 system at different expression levels  
374 of the anchor protein. The results indicate that anchor/bait ratios of around one to two allowed an  
375 optimal response to blue light for the LITESEC-act system. Higher ratios retain partial membrane  
376 sequestration under light conditions and subsequently impair T3SS activity in the activated stage;  
377 conversely, low ratios lead to incomplete sequestration and measurable T3SS activity under non-  
378 activating conditions (Fig. 5). Due to possible variations in transfer efficiency and the indirect nature  
379 of the anchor/bait ratio determination, this value might not be precise; however, our data strongly  
380 suggest a relatively tight “sweet spot” in the expression ratio of the two interacting proteins, which  
381 may be key for the successful optogenetic control of bacterial processes. This is in sharp contrast to  
382 the eukaryotic application of the LOVTRAP interaction switches where much higher anchor/bait  
383 concentrations were shown to be optimal<sup>35</sup>. We therefore propose that optimization of the  
384 anchor/bait expression ratio represents an important step in the design of optogenetically controlled  
385 processes in prokaryotes.

#### 386 Factors for controlling prokaryotic processes by optogenetic interaction switches

387 The successful development and application of the LITESEC system highlights some key features for  
388 the control of prokaryotic processes by optogenetic interaction switches. The target protein (in our  
389 case the essential T3SS component SctQ) (i) has to be functional as a fusion protein to an optogenetic  
390 interaction domain, (ii) must be present in the cytosol at least temporarily to allow sequestration to  
391 occur, and (iii) must not be functional when tethered to the membrane anchor protein. To fulfil the  
392 last criterion, the target protein may feature a) a specific place of action (such as the injectisome for  
393 SctQ in the present case), or b) a specific interaction interface that is rendered inaccessible by the  
394 interaction with the anchor. In eukaryotic systems, proteins have been sequestered to various  
395 structures including the plasma membrane or mitochondria. The simpler cellular organization of  
396 bacteria makes the inner membrane an obvious target for protein sequestration, to which interaction  
397 domains can be easily targeted to by the addition of N-terminal TMHs. While the nature of the TMH is  
398 likely to be secondary for the success of the application, the extended TatA TMH and a short glycine-  
399 rich linker worked well for our approach. Crucially, we found that the expression ratio between anchor  
400 and bait proteins is a key determinant for the success of LITESEC and, most, likely, similar approaches  
401 to control bacterial processes by light.

402 Light-controlled protein translocation into host cells

403 The T3SS is a very promising tool for protein delivery into eukaryotic cells, both in cell culture and in  
404 healthcare<sup>10,14,20</sup>. However, the T3SS indiscriminately injects cargo proteins into contacting host cells.  
405 Lack of targetability is therefore a main obstacle in the further development and application of this  
406 method<sup>20,21</sup>. Previous methods to control the activity of the T3SS relied on controlled expression of  
407 one or all components of the injectisome. For example, Song and colleagues expressed all components  
408 of the *Salmonella* SPI-1 T3SS from two inducible promoters in a clean expression system<sup>47</sup>, and Schulte  
409 *et al.* expressed the T3SS genes from a TetA promoter, which additionally allows the intracellular  
410 induction of the T3SS<sup>48</sup>. Besides the difficulty to specifically induce secretion in defined places *in situ*,  
411 the main drawback of these methods is the slow response (induction of expression and assembly of  
412 the T3SS take more than 60 min<sup>28,47,48</sup>). In addition, in these systems, the T3SS remains active as long  
413 as the induced protein(s) are still present, which leads to a higher risk of translocation into non-target  
414 cells.

415 By using light to specifically activate the modified T3SS in bacteria, we have addressed this issue. The  
416 LITESEC system allows to deliver proteins into host cells at a specific time and place. The system gives  
417 complete control over the secretion of heterologous T3SS cargo into the supernatant, either by  
418 providing illumination (LITESEC-act), or stopping the light exposure (LITESEC-supp). Importantly,  
419 secretion by the LITESEC-act system is temporary, and stopped within minutes after the end of  
420 illumination with blue light, thereby further reducing unspecific activation.

421 The LITESEC system presented in this work uses light-controlled sequestration of an essential dynamic  
422 T3SS component to precisely regulate the activity of the T3SS. This approach provides a new method  
423 for highly time- and space-resolved protein secretion and delivery into eukaryotic cells.

424

425 *Supporting information, including material and methods, can be found in the supplementary file.*

426

427 **Acknowledgements**

428 The authors would like to thank Prof. Andreas Gahlmann, University of Virginia, for important  
429 contributions and discussions during the inception of this study; Dr. Felicity Alcock, University of  
430 Oxford, for suggestions for the design of the transmembrane anchor; Dr. Seraphine Wegner, Max-  
431 Planck-Institute for Polymer Research, Mainz for helpful discussions about optogenetic interaction  
432 switches; Prof. Petra Dersch, University of Münster, Germany, for the gift of HEP-2 cells; as well as

433 Prof. Lars-Oliver Essen, University of Marburg, for input and support on the characterization of the  
434 optogenetic setup.

435

#### 436 **Competing interests**

437 A. Diepold and F. Lindner submitted a European patent application on the presented method. The  
438 authors declare no competing financial interests.

439

#### 440 **References**

- 441 1. Deng, W. *et al.* Assembly, structure, function and regulation of type III secretion systems. *Nat. Rev.*  
442 *Microbiol.* **15**, 323–337 (2017).
- 443 2. Wagner, S. *et al.* Bacterial type III secretion systems: A complex device for delivery of bacterial effector  
444 proteins into eukaryotic host cells. *FEMS Microbiol. Lett.* (2018). doi:10.1093/femsle/fny201
- 445 3. Erhardt, M., Namba, K. & Hughes, K. T. Bacterial nanomachines: the flagellum and type III injectisome. *Cold*  
446 *Spring Harb. Perspect. Biol.* **2**, a000299 (2010).
- 447 4. Diepold, A. & Armitage, J. P. Type III secretion systems: the bacterial flagellum and the injectisome. *Philos.*  
448 *Trans. R. Soc. B Biol. Sci.* **370**, 20150020 (2015).
- 449 5. Coburn, B., Sekirov, I. & Finlay, B. B. Type III secretion systems and disease. *Clin. Microbiol. Rev.* **20**, 535–49  
450 (2007).
- 451 6. Pettersson, J. *et al.* Modulation of virulence factor expression by pathogen target cell contact. *Science* (80-  
452 *).* **273**, 1231–3 (1996).
- 453 7. Cornelis, G. R. The Yersinia Ysc-Yop ‘type III’ weaponry. *Nat. Rev. Mol. Cell Biol.* **3**, 742–52 (2002).
- 454 8. Kudryashev, M. *et al.* In situ structural analysis of the Yersinia enterocolitica injectisome. *Elife* **2**, e00792  
455 (2013).
- 456 9. Cornelis, G. R. The type III secretion injectisome. *Nat. Rev. Microbiol.* **4**, 811–825 (2006).
- 457 10. Bai, F., Li, Z., Umezawa, A., Terada, N. & Jin, S. Bacterial type III secretion system as a protein delivery tool  
458 for a broad range of biomedical applications. *Biotechnol. Adv.* **36**, 482–493 (2018).
- 459 11. Schlumberger, M. C. *et al.* Real-time imaging of type III secretion: Salmonella SipA injection into host cells.  
460 *Proc. Natl. Acad. Sci. U. S. A.* **102**, 12548–12553 (2005).
- 461 12. Enninga, J., Mounier, J., Sansonetti, P., Tran Van Nhieu, G. & Nhieu, G. T. Van. Secretion of type III effectors  
462 into host cells in real time. *Nat. Methods* **2**, 959–65 (2005).
- 463 13. Mills, E., Baruch, K., Charpentier, X., Kobi, S. & Rosenshine, I. Real-time analysis of effector translocation by  
464 the type III secretion system of enteropathogenic Escherichia coli. *Cell Host Microbe* **3**, 104–13 (2008).
- 465 14. Ittig, S. J. *et al.* A bacterial type III secretion-based protein delivery tool for broad applications in cell biology.  
466 *J. Cell Biol.* **211**, 913–31 (2015).
- 467 15. Michiels, T., Wattiau, P., Brasseur, R., Ruyschaert, J. M. & Cornelis, G. R. Secretion of Yop proteins by  
468 Yersiniae. *Infect. Immun.* **58**, 2840–9 (1990).
- 469 16. Sory, M.-P., Boland, A., Lambermont, I. & Cornelis, G. R. Identification of the YopE and YopH domains  
470 required for secretion and internalization into the cytosol of macrophages, using the *cyaA* gene fusion  
471 approach. *Proc. Natl. Acad. Sci. U. S. A.* **92**, 11998–12002 (1995).
- 472 17. Jacobi, C. A. *et al.* *In vitro* and *in vivo* expression studies of *yopE* from *Yersinia enterocolitica* using the *gfp*  
473 reporter gene. *Mol. Microbiol.* **30**, 865–882 (1998).
- 474 18. Göser, V., Kommnick, C., Liss, V. & Hensel, M. Self-Labeling Enzyme Tags for Analyses of Translocation of  
475 Type III Secretion System Effector Proteins. *MBio* **10**, e00769-19 (2019).
- 476 19. Blanco-Toribio, A., Muyldermans, S., Frankel, G. & Fernández, L. Á. Direct Injection of Functional Single-  
477 Domain Antibodies from E. coli into Human Cells. *PLoS One* **5**, e15227 (2010).

- 478 20. Walker, B. J., Stan, G.-B. V & Polizzi, K. M. Intracellular delivery of biologic therapeutics by bacterial  
479 secretion systems. *Expert Rev. Mol. Med.* **19**, e6 (2017).
- 480 21. Felgner, S., Pawar, V., Kocijancic, D., Erhardt, M. & Weiss, S. Tumour-targeting bacteria-based cancer  
481 therapies for increased specificity and improved outcome. *Microb. Biotechnol.* **10**, 1074–1078 (2017).
- 482 22. Morita-ishihara, T. *et al.* Shigella Spa33 is an essential C-ring component of type III secretion machinery. *J.*  
483 *Biol. Chem.* **281**, 599–607 (2005).
- 484 23. Johnson, S. & Blocker, A. J. Characterization of soluble complexes of the Shigella flexneri type III secretion  
485 system ATPase. *FEMS Microbiol. Lett.* **286**, 274–8 (2008).
- 486 24. Biemans-Oldehinkel, E., Sal-Man, N., Deng, W., Foster, L. J. & Finlay, B. B. Quantitative proteomic analysis  
487 reveals formation of an EscL-EscQ-EscN type III complex in enteropathogenic Escherichia coli. *J. Bacteriol.*  
488 **193**, 5514–9 (2011).
- 489 25. Diepold, A. *et al.* A dynamic and adaptive network of cytosolic interactions governs protein export by the  
490 T3SS injectisome. *Nat. Commun.* **8**, 15940 (2017).
- 491 26. Hu, B., Lara-Tejero, M., Kong, Q., Galán, J. E. & Liu, J. In Situ Molecular Architecture of the Salmonella Type  
492 III Secretion Machine. *Cell* **168**, 1065–1074.e10 (2017).
- 493 27. Lara-Tejero, M. *et al.* Role of SpaO in the assembly of the sorting platform of a Salmonella type III secretion  
494 system. *PLoS Pathog.* **15**, e1007565 (2019).
- 495 28. Diepold, A. *et al.* Deciphering the assembly of the Yersinia type III secretion injectisome. *EMBO J.* **29**, 1928–  
496 1940 (2010).
- 497 29. Diepold, A., Wiesand, U., Amstutz, M. & Cornelis, G. R. Assembly of the Yersinia injectisome: the missing  
498 pieces. *Mol. Microbiol.* **85**, 878–92 (2012).
- 499 30. Lara-Tejero, M., Kato, J., Wagner, S., Liu, X. & Galán, J. E. A Sorting Platform Determines the Order of Protein  
500 Secretion in Bacterial Type III Systems. *Science (80-. )*. **331**, 1188–91 (2011).
- 501 31. Diepold, A., Kudryashev, M., Delalez, N. J., Berry, R. M. & Armitage, J. P. Composition, Formation, and  
502 Regulation of the Cytosolic C-ring, a Dynamic Component of the Type III Secretion Injectisome. *PLoS Biol.*  
503 **13**, e1002039 (2015).
- 504 32. Deisseroth, K. Optogenetics. *Nat. Methods* **8**, 26–29 (2011).
- 505 33. Toettcher, J. E., Voigt, C. A., Weiner, O. D. & Lim, W. A. The promise of optogenetics in cell biology:  
506 interrogating molecular circuits in space and time. *Nat. Methods* **8**, 35–8 (2011).
- 507 34. Guntas, G. *et al.* Engineering an improved light-induced dimer (iLID) for controlling the localization and  
508 activity of signaling proteins. *Proc. Natl. Acad. Sci.* **112**, 112–117 (2015).
- 509 35. Wang, H. *et al.* LOVTRAP: an optogenetic system for photoinduced protein dissociation. *Nat. Methods* **13**,  
510 755–8 (2016).
- 511 36. Zimmerman, S. P. *et al.* Tuning the Binding Affinities and Reversion Kinetics of a Light Inducible Dimer Allows  
512 Control of Transmembrane Protein Localization. *Biochemistry* **55**, 5264–71 (2016).
- 513 37. Mukherjee, A., Repina, N. A., Schaffer, D. V & Kane, R. S. Optogenetic tools for cell biological applications.  
514 *J. Thorac. Dis.* **9**, 4867–4870 (2017).
- 515 38. Kaniga, K., Delor, I. & Cornelis, G. R. A wide-host-range suicide vector for improving reverse genetics in  
516 gram-negative bacteria: inactivation of the blaA gene of Yersinia enterocolitica. *Gene* **109**, 137–41 (1991).
- 517 39. Diepold, A. & Wagner, S. Assembly of the bacterial type III secretion machinery. *FEMS Microbiol. Rev.* **38**,  
518 802–22 (2014).
- 519 40. Köberle, M. *et al.* Yersinia enterocolitica Targets Cells of the Innate and Adaptive Immune System by  
520 Injection of Yops in a Mouse Infection Model. *PLoS Pathog.* **5**, e1000551 (2009).
- 521 41. Autenrieth, S. E. *et al.* Immune Evasion by Yersinia enterocolitica: Differential Targeting of Dendritic Cell  
522 Subpopulations In Vivo. *PLoS Pathog.* **6**, e1001212 (2010).
- 523 42. Westerhausen, S. *et al.* A NanoLuc luciferase-based assay enabling the real-time analysis of protein  
524 secretion and injection by bacterial type III secretion systems. *bioRxiv* 745471 (2019). doi:10.1101/745471
- 525 43. Charpentier, X. & Oswald, E. Identification of the secretion and translocation domain of the  
526 enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a  
527 new fluorescence-based reporter. *J. Bacteriol.* **186**, 5486–95 (2004).
- 528 44. Marketon, M. M., DePaolo, R. W., DeBord, K. L., Jabri, B. & Schneewind, O. Plague bacteria target immune

- 529 cells during infection. *Science* (80-. ). **309**, 1739–41 (2005).
- 530 45. Kawano, F., Suzuki, H., Furuya, A. & Sato, M. Engineered pairs of distinct photoswitches for optogenetic  
531 control of cellular proteins. *Nat. Commun.* **6**, 6256 (2015).
- 532 46. Kawano, F., Aono, Y., Suzuki, H. & Sato, M. Fluorescence Imaging-Based High-Throughput Screening of Fast-  
533 and Slow-Cycling LOV Proteins. *PLoS One* **8**, e82693 (2013).
- 534 47. Song, M. *et al.* Control of type III protein secretion using a minimal genetic system. *Nat. Commun.* **8**, 14737  
535 (2017).
- 536 48. Schulte, M. *et al.* A versatile remote control system for functional expression of bacterial virulence genes  
537 based on the tetA promoter. *Int. J. Med. Microbiol.* (2018). doi:10.1016/j.ijmm.2018.11.001
- 538 49. Hueck, C. J. Type III protein secretion systems in bacterial pathogens of animals and plants. *Microbiol. Mol.*  
539 *Biol. Rev.* **62**, 379–433 (1998).
- 540